CVS Health Corp. closed 31.03% short of its 52-week high of $80.75, which the company reached on March 28th.

A new FTC report found that pharmacy benefit managers have inflated the price of life-saving generic prescription drugs, finding the companies sometimes increased prices of these drugs by 1,000 ...

Pharmacy benefit managers overcharged for specialty generic medications — in many cases by hundreds and thousands of percent ...

One of the new features included in the app, is the ability for customers to unlock merchandise locked up on shelves in ...

CVS Health (CVS) on Tuesday announced the launch of the CVS Health app. The app, a successor to the CVS Pharmacy app and one of many ...

CVS Health is rolling out a new customer app that aims to make it simpler and more convenient for users to manage health ...

Leerink Partners maintained a Market Perform rating on CVS Health (NYSE:CVS) shares while increasing the price target from $51.00 to $55.00. The adjustment reflects the firm's expectation of an ...

When talking about the influence of pharmacy benefit managers ... the Federal Trade Commission concluded CVS Caremark, ...

At the macro level, political rhetoric levied at PBMs (Pharmacy Benefit Managers) and Medicare Advantage plan insurers was at high tide. PBMs and MA plans are core to the CVS Caremark and Aetna ...

More Eugene Gologursky/Getty Images On Tuesday, the FTC released a report that said the three largest pharmacy ... and CVS Caremark has a long track record of making specialty drugs more affordable.

“Across brand, generic, and specialty prescription drugs, CVS Caremark reimburses independent pharmacies at higher levels than CVS Pharmacy. Further, our member out-of-pocket costs have been reduced ...

Express Scripts and CVS Caremark Rx, inflated the prices of specialty generic medications, particularly those that treat cancer, heart disease, and HIV. The report found that these “Big 3 ...